BioNeutral Group, Inc. Appoints Dr. Donald Goldmann, M.D. to its Scientific Advisory Board

NEWARK, N.J.--(Business Wire)--
BioNeutral Group, Inc. (OTCBB: BONU), a chemical technology-based Life Science
company that intends to commercialize a novel combinational chemistry-based
technology, today announced that the Company has appointed Dr. Donald Goldmann,
M.D. to the Scientific Advisory Board. BioNeutral Group will be focusing its
attention in areas which Dr. Goldmann has considerable expertise including
hospital borne infections and bio-preparedness.

Dr. Goldmann is Professor of Pediatrics at Harvard Medical School and Professor
of Immunology and Infectious Diseases and Epidemiology at the Harvard School of
Public Health. He teaches a Harvard College Freshman Seminar, "The Impact of
Infectious Diseases on History and Society." Dr. Goldmann's work has focused on
preventing and controlling hospital-acquired infections. His applied research in
the health services arena focuses on quality measurement and improvement,
clinical practice guideline development and evaluation, assessment of parental
perceptions of care, and patient safety.

Dr. Goldmann served on CDC`s Hospital Infection Control Practices Advisory
Committee and chaired the taskforce that developed national guidelines for the
use of a glycopeptide antibiotic, vancomycin. He and his colleagues used
infection control as a model for quality assessment and improvement in
developing countries including Brazil, Thailand, and Indonesia (development of
validated methods to assess the structure, processes, and outcomes of infection
control programs), Hungary and Poland (training of multidisciplinary QI teams
and national surveillance), Colombia (reduction in C-section infections using QI
interventions), Russia (national infection control training initiative and
center-specific interventions), Ukraine (hospital assessments and microbiology
laboratory capacity), Mexico, (use of QI methods to prevent pediatric nosocomial
infection) and the Philippines (infection prevention collaborative and a
clinical trial of interventions to reduce antibiotic resistance in academic
NICUs).

Dr. Donald Goldmann is a graduate of Harvard Medical School. He completed an
internship, residency, and fellowship at Massachusetts General Hospital. He
served as an Epidemic Intelligence Service Officer of the Centers for Disease
Control.

"I am looking forward to working with other members of the Scientific Advisory
Board on Ygiene, which has very interesting and promising properties," said Dr.
Goldmann. "Based on my experience in combating hospital infections, we certainly
need compounds with sporicidal activity."

Dr. Andrew Kielbania, Chief Scientist for BioNeutral Group, Inc. stated "The
addition of Dr. Goldmann to our Scientific Advisory Board is an important step
for BioNeutral. With his expertise and understanding of the unmet needs in the
healthcare arena, Dr. Goldmann will provide us invaluable insight as we launch
our new products into the healthcare market."

"We are extremely pleased to welcome Dr. Goldmann as the newest member of our
multi-talented and highly credentialed advisory board. He brings with him many
years of hands on expert field experience both at the CDC level and from
numerous third world countries where the greatest threat of a pandemic would
originate. I am confident that he will bring tremendous added value to our
already ground breaking technology platforms," said Stephen J. Browand,
President and CEO of BioNeutral Group, Inc.

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New
Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science
company that intends to commercialize a novel combinational chemistry-based
technology which can neutralize harmful environmental contaminants, toxins and
dangerous micro-organisms including bacteria, viruses, mold, fungi and spores.
The formulations, including Ygiene and Ogiene, which are eco-friendly and
include natural and common ingredients which are found in baby products and in
every day foods. The Company has combined these widely-used compounds in highly
specialized ways to create products that dramatically enhance disinfecting and
cleaning results; products include BioNeutralizers and ChemoNeutralizers.
BioNeutral`s proprietary platform technology has been proven effective in
surface, water and airborne applications.

More information about the Company may be found at www.bioneutralgroup.com.

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors.
The results are published to let shareholders know how the Company's technology
compares with known formulations in the market place. Any product claim for
antimicrobial activity requires approval from the EPA or FDA, depending upon
where and how the formulations are used. The EPA and FDA have not reviewed or
confirmed the Company's data and findings. BioNeutral's antimicrobial
formulations will be marketed under the brand name Ygiene and are not yet
available for sale in the United States.

Under The Private Securities Litigation Reform Act of 1995: The statements in
the press release that relate to the Company's expectations with regard to the
future impact on the Company's results from new products in development are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements are subject to risks and
uncertainties. Words such as "expects," "intends," "plans," "may," "could,"
"should," "anticipates," "likely," "believes" and words of similar import also
identify forward-looking statements. Forward-looking statements are based on
current facts and analyses and other information that are based on forecasts of
future results, estimates of amounts not yet determined and assumptions of
management. Readers are urged not to place undue reliance on the forward-looking
statements, which speak only as of the date of this release. We assume no
obligation to update any forward-looking statements in order to reflect any
event or circumstance that may arise after the date of this release. Additional
information on risks and other factors that may affect the business and
financial results of BioNeutral Group can be found in the filings of BioNeutral
Group with the U.S. Securities and Exchange Commission.

BioNeutral Group Inc.
Stephen J. Browand, President and CEO
steve@bioneutralgroup.com
or
Investor Relations
Corporate Evolutions, Inc.
Ph: 516-482-0155
Toll Free: 877-482-0155
info@corporateevolutions.com
www.corporateevolutions.com

Copyright Business Wire 2009